MARCOS VALDEZ: Open Payments
NPI 1043874324 · PRICE, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$696 in 36 payments from 20 companies in 2025. Trend: 2023 $381 · 2024 $394 · 2025 $696
Food & beverage: $696
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $215 |
| AstraZeneca Pharmaceuticals LP | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Amgen Inc. | 2 | $39 |
| Novo Nordisk Inc | 2 | $36 |
| PFIZER INC. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $26 |
| SANOFI-AVENTIS U.S. LLC | 1 | $26 |
| Organon LLC | 1 | $25 |
Products named: VRAYLAR, REXULTI, UBRELVY, EVENITY, NURTEC ODT, FARXIGA, Qelbree, TZIELD.
Industry payments across UT — which companies pay providers there.
